<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5094">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040622</url>
  </required_header>
  <id_info>
    <org_study_id>16-2583</org_study_id>
    <nct_id>NCT03040622</nct_id>
  </id_info>
  <brief_title>The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial</brief_title>
  <official_title>The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate thrombogenicity in patients undergoing left atrial appendage
      closure using the WATCHMAN device. Parameters of thrombosis and platelet function, as well
      as other bio-markers, will be measure before, during, and after WATCHMAN implantation at
      several follow up visits.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Aggregation measured by Light Transmissions Aggregometry with 5 and 20 ÂµM ADP, 2mM AA, and 4ug/ml collagen as agonists.</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombelastography preformed to determine physical characteristics of the platelet-fibrin clot.</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin generation measured by thrombogram (CAT assay) to identify patients with hypo- or hypercoagulable phenotypes.</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarker measurements to determine any that may predict thrombo-embolic events.</measure>
    <time_frame>12 Months</time_frame>
    <description>Biomarkers include fibrinogen, d-dimer, hsCRP, PAI, Urninary TxB2, sST2, and Galectin-3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Atrial Thrombus measured by transesophageal echocardiography (TEE).</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major or clinically-relevant non-major bleeding.</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of high on-treatment platelet reactivity.</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of low, medium, and high risk thrombogenic phenotype within the study population.</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Left Atrial Appendage Closure</condition>
  <condition>WATCHMAN Device Implantation</condition>
  <arm_group>
    <arm_group_label>Watchman Left Atrial Appendage Closure</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WATCHMAN Left Atrial Appendage Closure</intervention_name>
    <description>WATCHMAN Left Atrial Appendage Closure</description>
    <arm_group_label>Watchman Left Atrial Appendage Closure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects &gt;18 years of age scheduled for left atrial appendage closure procedure with the
        WATCHMAN device.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject indicated and scheduled for WATCHMAN device implantation at IHVI.

          -  Subject may be of either sex and of any race, and must be &gt;18 years of age.

          -  Subject must be willing and able to give appropriate informed consent.

          -  The subject is able to read and has signed and dated the informed consent document
             including authorization permitting release of personal health information approved by
             the investigator's Institutional Review Board (IRB).

        Exclusion Criteria:

        - Subjects with contraindications for WATCHMAN device implantation Intracardiac thrombus
        is visualized by echocardiographic imaging An atrial septal defect repair or closure
        device or a patent foramen ovale repair or closure device is present The LAA anatomy will
        not accommodate a device Any of the customary contraindications for other percutaneous
        catheterization procedures (e.g., patient size too small to accommodate TEE probe or
        required catheters) or conditions (e.g., active infection, bleeding disorder) are present.

        There are contraindications to the use of warfarin, aspirin, or clopidogrel The patient
        has a known hypersensitivity to any portion of the device material or the individual
        components such that the use of the WATCHMAN Device is contraindicated

          -  Concurrent participation in any investigational study.

          -  Subject likely to not be available to complete all protocol-required study visits or
             procedures, to the best of the subject's and investigator's knowledge

          -  History or evidence of any other clinically significant disorder, condition, or
             disease other than those outlined above that, in the opinion of the investigator, may
             compromise the ability of the subject to give written informed consent, would pose a
             risk to subject safety or interfere with the study evaluation, procedures, or
             completion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kevin Bliden, BS, MBA</last_name>
    <phone>703-776-7702</phone>
    <email>kevin.bliden@inova.org</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>January 4, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>WATCHMAN</keyword>
  <keyword>Left Atrial Appendage Closure</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Platelet Function</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
